Chiasma Stock Shoots Up On Being Acquired By Amryt Pharma In All Stock Deal

• Amryt Pharma (NASDAQ: AMYT) has agreed to acquire Chiasma Inc (NASDAQ: CHMA) in an all-stock combination. Each Chiasma shares will be exchanged for 0.396 Amryt American Depositary Shares, each representing five Amryt ordinary shares.

• The transaction is expected to accelerate and diversify Amryt's growing revenues, and Amryt expects to deliver estimated annual cost synergies of approximately $50M.

• Dr. Joe Wiley, Chief Executive Officer of Amryt, said, "this deal further solidifies our position as a global leader in treating rare and orphan conditions."

• The combined business will have three approved commercial products, and the combined portfolio of products offers a pathway to a potential $1 billion of peak revenues.

• Lead development candidate, Oleogel-S10, is currently progressing through the regulatory process in the US and EU and, if approved, will bring a portfolio of commercial products to four.

• Management will host a webcast and conference call today at 8:30 A.M. ET.

• Price Action: AMYT shares fell 0.31% at $12.80, CHMA shares are up 37% to $3.88 in the premarket trading session on the last check Wednesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Novo Nordisk's Q1 Sales Buoyed By GLP-1 Products, Lifts FY21 Guidance

• Alcon's Q1 Sales Boosted By Equipment, Implantables In Surgical Segment, FY21 Outlook In-Line With Expectations

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.